Rhumbline Advisers Has $1.65 Million Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Rhumbline Advisers increased its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 7.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 36,486 shares of the company’s stock after acquiring an additional 2,425 shares during the period. Rhumbline Advisers’ holdings in USANA Health Sciences were worth $1,651,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in USNA. Panagora Asset Management Inc. boosted its position in USANA Health Sciences by 143.1% during the second quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock worth $1,307,000 after purchasing an additional 16,999 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of USANA Health Sciences by 5.6% in the second quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock worth $4,405,000 after buying an additional 5,205 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of USANA Health Sciences by 32.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 109,252 shares of the company’s stock worth $4,943,000 after buying an additional 27,053 shares during the period. SG Americas Securities LLC acquired a new position in USANA Health Sciences in the 2nd quarter valued at $340,000. Finally, First Hawaiian Bank raised its holdings in USANA Health Sciences by 36.9% in the 2nd quarter. First Hawaiian Bank now owns 12,439 shares of the company’s stock worth $563,000 after acquiring an additional 3,350 shares during the period. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Trading Down 3.9 %

Shares of USANA Health Sciences stock opened at $38.63 on Friday. USANA Health Sciences, Inc. has a 1 year low of $36.05 and a 1 year high of $60.90. The company’s fifty day simple moving average is $40.90 and its 200-day simple moving average is $44.45. The company has a market cap of $735.94 million, a price-to-earnings ratio of 12.03, a PEG ratio of 1.28 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.11). The company had revenue of $212.87 million for the quarter, compared to the consensus estimate of $218.64 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same quarter in the previous year, the firm posted $0.89 EPS. As a group, research analysts forecast that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at USANA Health Sciences

In related news, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John Turman Fleming sold 1,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock worth $311,670 over the last three months. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. DA Davidson decreased their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, July 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.